Ana Carolina R G Maia

Dr. Ana Carolina R G Maia

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Experimental Parasitology
Verified
Journal Article
Closed access
AMAna Carolina R G Maia
Ana Carolina R G Maia
GPGabriane Nascimento Porcino
Gabriane Nascimento Porcino
MDMichelle Lima Detoni
Michelle Lima Detoni
LQLeonardo Ramos Quellis
Leonardo Ramos Quellis
NENayara Braga Emidio
Nayara Braga Emidio
EVEveline Gomes Vasconcelos
Eveline Gomes Vasconcelos

1 July 2019 in Veterinary Parasitology
Verified
Journal Article
Closed access
AMAna Carolina R G Maia
Ana Carolina R G Maia
GPGabriane Nascimento Porcino
Gabriane Nascimento Porcino
PPPriscila de F. Pinto
Priscila de F. Pinto
TMTúlio Vieira Mendes
Túlio Vieira Mendes
LALuciana Maria Ribeiro Antinarelli
Luciana Maria Ribeiro Antinarelli
EVEveline Gomes Vasconcelos
Eveline Gomes Vasconcelos

4 November 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
AKAlexandra Kolas
Alexandra Kolas
YRYudi Rusman
Yudi Rusman
AMAna Carolina R G Maia
Ana Carolina R G Maia
JWJessica Williams
Jessica Williams
Jiashu XieJiashu Xie
Jiashu Xie
CSChristine Salomon
Christine Salomon
Cryptosporidium is a waterborne gastrointestinal parasite that causes diarrheal disease worldwide. Currently, there are no effective therapeutics to treat cryptosporidiosis. Since natural products are a known source of anti-parasitic compounds, we screened a library of extracts and pure compounds isolated from bacteria and fungi collected from subterranean environments for anti-Cryptosporidium activity. Seven norditerpene lactones isolated from the fungus Oidiodendron truncatum collected from the Soudan Iron mine in Minnesota showed potent activity and were further tested to identify the most active compounds. The availability of a diverse suite of natural structural analogs with varying activities allowed us to determine some structure–activity relationships for both anti-parasitic activity and cytotoxicity. The two most potent compounds, oidiolactones A and B, had EC50s against C. parvum of 530 and 240 nM, respectively, without cytotoxicity to host cells. Both compounds also inhibited the related parasite Toxoplasma gondii. Oidiolactone A was active against asexual, but not sexual, stages of C. parvum, and killed parasites within 8 h of treatment. This compound reduced C. parvum infection by 70% in IFNγ−/− mice, with no signs of toxicity. The high potency, low cytotoxicity, and in vivo activity combined with high production and synthetic accessibility make these oidiolactones attractive scaffolds for the development of new anti-Cryptosporidium therapeutics.